Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BMS-962476 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Panel 1: BMS-962476 SC (0.01 mg/Kg) or Placebo | EXPERIMENTAL | BMS-962476 0.01 mg/kg or Placebo matching with BMS-962476 0 mg liquid subcutaneously (SC), Single Dose, 1 day |
| Panel 2: BMS-962476 SC (0.03 mg/Kg) or Placebo | EXPERIMENTAL | BMS-962476 0.03 mg/kg or Placebo matching with BMS-962476 0 mg liquid subcutaneously (SC), Single Dose, 1 day |
| Panel 3: BMS-962476 SC (0.1 mg/Kg) or Placebo | EXPERIMENTAL | BMS-962476 0.1 mg/kg or Placebo matching with BMS-962476 0 mg liquid subcutaneously (SC), Single Dose, 1 day |
| Panel 4: BMS-962476 SC (0.3 mg/Kg) or Placebo | EXPERIMENTAL | BMS-962476 0.3 mg/kg or Placebo matching with BMS-962476 0 mg liquid subcutaneously (SC), Single Dose, 1 day |
| Panel 5: BMS-962476 IV (0.3 mg/Kg) or Placebo | EXPERIMENTAL | BMS-962476 0.3 mg/kg or Placebo matching with BMS-962476 0 mg liquid intravenously (IV), Single Dose, 1 day |
| Panel 6: BMS-962476 IV (1.0 mg/Kg) or Placebo | EXPERIMENTAL | BMS-962476 1.0 mg/kg or Placebo matching with BMS-962476 0 mg liquid intravenously (IV), Single Dose, 1 day |
| Panel 7: Statin + BMS-962476 SC (0.1 mg/Kg) or Placebo | EXPERIMENTAL | BMS-962476 0.1 mg/kg or Placebo matching with BMS-962476 0 mg liquid subcutaneously (SC), Single Dose, 1 day |
| Panel 8: Statin + BMS-962476 SC (0.3 mg/Kg) or Placebo | EXPERIMENTAL | BMS-962476 0.3 mg/kg or Placebo matching with BMS-962476 0 mg liquid subcutaneously (SC), Single Dose, 1 day |
| Name | Type | Description |
|---|---|---|
| BMS-962476 | BIOLOGICAL | - |
| Placebo matching with BMS-962476 | BIOLOGICAL | - |
Inclusion Criteria: * Healthy population * Untreated low density lipoprotein cholesterol (LDL-c) ≥ 130 and ≤ 190 mg/dL and triglycerides ≤ 200 mg/dL * Body Mass Index (BMI) of 18 to 35 kg/m2 inclusive * Men and women, ages 18 to 65 years, inclusive * Statin population * Patients with hype...
BMS-962476 is an investigational monoclonal antibody being developed for the treatment of atherosclerosis, a condition characterized by the buildup of plaque in the arteries. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
BMS-962476 is being developed by Bristol-Myers Squibb Company, a biopharmaceutical company listed on the New York Stock Exchange under the ticker symbol BMY. The drug is in Phase 1 clinical development for the treatment of atherosclerosis.
BMS-962476 is in Phase 1 clinical development. It is an investigational drug and has not yet received regulatory approval. The drug is being studied for its safety and tolerability in patients with elevated cholesterol and atherosclerosis.
BMS-962476 has one completed Phase 1 clinical trial, identified as NCT01587365. This was a single ascending dose safety study conducted in healthy subjects and patients with elevated cholesterol on statins. The trial enrolled 66 participants and was conducted in the United States.
BMS-962476 is a distinct investigational monoclonal antibody developed by Bristol-Myers Squibb. It is not known to be the same as any other marketed drug. It is being studied specifically for its potential role in treating atherosclerosis.